Spruce Biosciences Achieves Proof of Concept in Phase 2 Study of Tildacerfont in Congenital Adrenal Hyperplasia
25 March 2019
– Tildacerfont demonstrates meaningful reduction in key disease biomarkers adrenocorticotropic hormone (ACTH), 17-hydroxyprogesterone (17-OHP) and androstenedione (A4)
– Well-tolerated and safe, tildacerfont holds potential as a treatment for patients with congenital adrenal hyperplasia, a rare endocrine disorder
Spruce Biosciences Announces Presentation of Positive Topline Data from Phase 2 Study of Tildacerfont (SPR001) in Congenital Adrenal Hyperplasia at the 2019 Annual Meeting of the Endocrine Society (ENDO)
08 March 2019
Tildacerfont demonstrates potential to become the first approved therapy for congenital adrenal hyperplasia, a rare endocrine disorder
IN THE NEWS
Spruce clears phase II hurdle with lead asset for rare endocrine disorder
26 March 2019
Spruce Biosciences’ tildacerfont (SPR-001) for congenital adrenal hyperplasia (CAH), a rare endocrine disorder, passed muster in a phase II experiment. Proof-of-concept data were disclosed at the Endocrine Society’s annual meeting in New Orleans, ENDO 2019, for the oral corticotrophin-releasing factor type 1 receptor antagonist.
Neurocrine Shines In Congenital Adrenal Hyperplasia, But Competitor Is Close
13 March 2019
Spruce’s competing drug with same mechanism of action is also in Phase II, with data expected at the end of March.